Gene Location [1]
Receptor tyrosine kinase/growth factor signaling

FGFR4 Mutation is present in 1.42% of AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence [4].

Top Disease Cases with FGFR4 Mutation

Significance of FGFR4 Mutation in Diseases

Malignant Solid Tumor +

Urothelial Carcinoma +

Cholangiocarcinoma +

Cancer +

Non-Hodgkin Lymphoma +

Multiple Myeloma +

Endometrial Carcinoma +

Glioblastoma +

Non-Small Cell Lung Carcinoma +

Gastric Carcinoma +

Anaplastic Astrocytoma +

Breast Carcinoma +

Sarcoma +

Intrahepatic Cholangiocarcinoma +

Squamous Cell Lung Carcinoma +

Anaplastic Oligodendroglioma +

Gastrointestinal Stromal Tumor +

Extrahepatic Cholangiocarcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Myeloproliferative Neoplasm +

Non-Muscle Invasive Bladder Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.